GlassScriptPhysician profile
Yusuf Qamruzzaman
NPI 1174738231
$4,120.81
in general payments reported to CMS, 2019-2025
50 companies · $920 in 2025
The $920 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $125 · 2021: $87.51 · 2022: $568 · 2023: $941 · 2024: $777 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.71 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $412.35 | 2019-2025 | |
| Genentech USA, INC. | $267.38 | 2019-2025 | Tecentriq, Venclexta, Alecensa |
| Astrazeneca Pharmaceuticals LP | $239.91 | 2019-2025 | Calquence |
| Amgen INC. | $227.95 | 2019-2023 | Kyprolis, Blincyto |
| Janssen Biotech, INC. | $226.71 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Genmab U.S., INC. | $206.94 | 2024-2025 | Epkinly |
| Pfizer INC. | $179.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $166.60 | 2019-2023 | Opdivo |
| Glaxosmithkline, LLC. | $127.01 | 2020-2025 | Ojjaara, Shingrix, Zejula |
| Eisai INC. | $116.65 | 2023-2025 | |
| Array Biopharma INC | $115.07 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Abbvie INC. | $113.90 | 2024-2025 | |
| Seagen INC. | $102.93 | 2021-2023 | Padcev, Tukysa |
| Astellas Pharma US INC | $98.22 | 2019-2024 | Padcev |
| Gilead Sciences, INC. | $96.61 | 2019-2025 | Trodelvy |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $92.69 | 2024-2025 | Yescarta |
| Rigel Pharmaceuticals, INC. | $90.40 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Aveo Pharmaceuticals, INC. | $88.12 | 2022-2025 | Fotivda |
| Genzyme Corporation | $81.89 | 2019-2025 | |
| Daiichi Sankyo INC. | $79.67 | 2023-2024 | Enhertu, Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $77.60 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Kyowa Kirin, INC. | $73.37 | 2023-2025 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $69.22 | 2019-2023 | Imbruvica |
| Taiho Oncology, INC. | $61.72 | 2019-2025 | |
| Celgene Corporation | $61.66 | 2020-2023 | Opdualag, Reblozyl |
| Tersera Therapeutics LLC | $57.25 | 2022-2025 | Xermelo |
| Mirati Therapeutics, INC. | $43.14 | 2024 | Krazati |
| Puma Biotechnology, INC. | $39.98 | 2022-2024 | |
| Mylan Institutional INC. | $37.85 | 2022-2023 | Fulphila, Ogivri |
| Bayer Healthcare Pharmaceuticals INC. | $35.00 | 2020-2024 | |
| Deciphera Pharmaceuticals INC. | $34.53 | 2023 | Qinlock |
| Springworks Therapeutics, INC. | $33.05 | 2024-2025 | Ogsiveo |
| Takeda Pharmaceuticals U.S.A., INC. | $32.27 | 2024 | Alunbrig |
| Lilly USA, LLC | $31.50 | 2019-2022 | |
| Stemline Therapeutics INC. | $31.46 | 2023 | Elzonris |
| Exelixis INC. | $28.22 | 2023-2025 | Cabometyx |
| Amag Pharmaceuticals, INC. | $27.56 | 2021 | |
| Emmaus Medical, INC. | $23.74 | 2021-2023 | Endari |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $19.54 | 2022 | |
| Spectrum Pharmaceuticals INC. | $17.14 | 2019 | |
| Immunocore Limited | $16.54 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.09 | 2022 | |
| Cti Biopharma Corp. | $15.47 | 2023 | Vonjo |
| Karyopharm Therapeutics INC. | $14.65 | 2020 | |
| Novo Nordisk INC | $14.54 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.06 | 2020 | |
| Sumitomo Pharma America, INC. | $14.05 | 2023 | Orgovyx |
| Iovance Biotherapeutics, INC. | $13.71 | 2025 | Amtagvi |
| Morphosys, US INC. | $13.40 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusuf Qamruzzaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.